Imatinib

Vero E6 cells seeded on a 96-well plate were treated with either amuvatinib (Selleckchem, USA) or imatinib (Axon Medchem, Netherlands). At the indicated time points, cell viability was measured using 30 μL of water-soluble tetrazolium salt (WST; Dail Lab, South Korea) as reported previously (47 (link)).

Vero E6 cells seeded on a 96-well plate were treated with either amuvatinib (Selleckchem, USA) or imatinib (Axon Medchem, Netherlands). At the indicated time points, cell viability was measured using 30 μL of water-soluble tetrazolium salt (WST; Dail Lab, South Korea) as reported previously (47 (link)).

Both imatinib and dasatinib, tyrosine kinase-specific inhibitors, were purchased from Axon Medchem. Bafilomycin A1 and Texas Red conjugated transferrin were purchased from Sigma–Aldrich. Sofosbuvir (PSI-7977) was purchased from MedChem Express. Antibodies were purchased from the following sources: rabbit anti-Abl kinase antibodies, anti-phosphor-CRKL (Y207) antibodies, and anti-EGFR antibodies from Cell Signaling; anti-clathrin heavy chain antibodies, and anti-CD81 neutralizing antibodies from BD bioscience; anti-β-actin antibodies from Sigma–Aldrich. Rabbit anti-NS5A, anti-NS3, and anti-core antibodies have been described elsewhere (Ngo et al., 2013 (link)). HCV E2 antibody was a gift from Dr. Jean Dubuisson (Institut Pasteur de Lille). Transfection reagents used were either Lipofectamine 2000 (Invitrogen, Carlsbad, CA, United States) or polyethyleneimine (Sigma–Aldrich).